Clinical Trial Update: Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Imdusiran (AB-729) with intermittent Durvalumab dosing in chronic hepatitis B subjects has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Durvalumab (durvalumab)
• Imdusiran (AB-729)

Snippet

Sponsor: Arbutus Biopharma Corporation | Conditions: Hepatitis B, Chronic | Phase 2 | Status: WITHDRAWN